Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.

By R. Timmerman, R. Mcgarry, C. Yiannoutsos, L. Papiez, K. Tudor, Jill Deluca, M. Ewing, R. Abdulrahman, C. DesRosiers, Mark D. Williams and 1 more. Journal of Clinical Oncology, 2006

1,363 citations recorded by the source corpus.

Subfields: Hepatology, Pulmonary and Respiratory Medicine, Radiation

View Paper: https://www.semanticscholar.org/paper/8e27dac13f578bc7d1e5e2e380e06af876b2137b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Fakiris
2. R. Paulus
3. C. Yiannoutsos
4. J. Galvin
5. R. Mcgarry
6. J. Bradley
7. J. Michalski
8. H. Choy

Citations in the corpus

• Stereotactic body radiation therapy for inoperable early stage lung cancer. (2010, background): “Instead, a rate of 60% was chosen as the lowest acceptable primary tumor control rate after taking into consideration the primary tumor control rate of greater than 80% seen in the Indiana University study.(9) Assuming an exponential distribution of time to primary tumor progression, the hazard rate”
• Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. (2009, result): “Our observation of a high rate of LC when using 60 Gy in three fractions is consistent with the reported LC rate when using the same high dose in medically inoperable non–small-cell lung cancer.(23) A summary of prospective, phase II studies that use SBRT for the treatment of liver metastases is lis”
• Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. (2009, background): “In the preliminary report of our study, we demonstrated a significantly decreased time to Grade 3 to 5 toxicity in patients with centrally located tumors (21).”